Related Experiment Video

Updated: Feb 8, 2026

Ex Vivo Infection of Live Tissue with Oncolytic Viruses
12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

13.4K

Oncolytic Viruses as Therapeutic Tools for Pediatric Brain Tumors

Maider Varela-Guruceaga1,2, Sonia Tejada-Solís3,4, Marc García-Moure5,6

  • 1The Health Research Institute of Navarra (IDISNA), 31008 Pamplona, Spain. mvarelag@unav.es.

Cancers
|July 11, 2018
PubMed

Insights

Oncolytic viruses (OVs) show promise for treating pediatric brain tumors (PBTs), offering a safer alternative to traditional therapies. Further research is needed to understand their interaction with the immune system in PBT treatment.

Area of Science:

  • Neuro-oncology
  • Virology
  • Immunology

Background:

  • Pediatric brain tumors (PBTs) remain a leading cause of childhood cancer mortality.
  • Current treatments for PBTs have limitations, including poor prognosis for some types and long-term adverse effects.
  • Oncolytic viruses (OVs) present a promising therapeutic avenue due to their demonstrated safety and tolerability.

Purpose of the Study:

  • To review oncolytic viruses (OVs) investigated for pediatric brain tumors (PBTs), primarily in preclinical settings.
  • To discuss future research directions for OV therapy in PBTs.
  • To highlight the role of the immune system in OV efficacy and the challenges in studying it within PBT models.

Main Methods:

  • Literature review of preclinical and clinical studies on oncolytic viruses for pediatric brain tumors.
  • Analysis of the antitumoral mechanisms of OVs, focusing on immune response stimulation.
  • Discussion of experimental challenges, particularly the lack of immunocompetent models for PBTs.

Main Results:

  • Oncolytic viruses (OVs) have been evaluated in various pediatric brain tumor (PBT) models, predominantly in preclinical studies.
  • OV efficacy is linked to the stimulation of an anti-tumor immune response, crucial for complete tumor eradication.
  • The role of the immune system in OV therapy for PBTs requires further investigation.

Conclusions:

  • Oncolytic viruses (OVs) are a viable therapeutic strategy for pediatric brain tumors (PBTs), offering improved safety profiles.
  • Understanding and harnessing the immune response is critical for maximizing OV therapeutic potential in PBTs.
  • Development of immunocompetent PBT models is essential for advancing OV research and clinical translation.
Keywords:
immunostimulationoncolytic viruspediatric brain tumors

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.9K
Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

7.5K

Related Concept Videos

What are Viruses?00:50

What are Viruses?

Overview
128.3K
Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
6.9K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
266
Therapeutic Communication01:30

Therapeutic Communication

Communication is a lifelong learning process. Through therapeutic communication, nurses can collect relevant assessment data, provide education and counseling, and interact during nursing interventions. Sending and receiving messages occur through verbal and nonverbal communication techniques and can happen separately or simultaneously.
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
8.5K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
317
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
237